Use of midazolam in palliative care
- 1 July 1991
- journal article
- research article
- Published by SAGE Publications in Palliative Medicine
- Vol. 5 (3) , 244-249
- https://doi.org/10.1177/026921639100500310
Abstract
Objective: To review the use of midazolam (a water-soluble benzodiazepine) in terminally ill patients. Design: A retrospective study of 104 patients. Results: Midazolam was used intravenously as sedation before minor procedures in three patients. Because of prolonged sedation in two patients, the following regimen is now used: 1 mg intravenously stat, followed by 1 mg/min, or 0.5mg/min in those over 65. In other situations, midazolam was used subcutaneously (SC), usually via a syringe driver. For muscle relaxation the median dose was 30mg SC/24h (27 patients; range 10-60mg). When treating terminal agitated delirium the median dose was 35mg SC/24h (61 patients; range 10-240mg). For multifocal myoclonus or as prophylaxis against fits the median dose was 30mg SC/24h (12 patients; range 15-80mg).Keywords
This publication has 8 references indexed in Scilit:
- Subcutaneous midazolam infusion in palliative careJournal of Pain and Symptom Management, 1990
- The use of subcutaneous midazolam in the home care settingPalliative Medicine, 1989
- Delirium in the Elderly PatientNew England Journal of Medicine, 1989
- MIDAZOLAM IN TERMINAL CAREThe Lancet, 1988
- Clinical Pharmacokinetics of Long-Term Infusion of Midazolam in Critically Ill Patients — Preliminary ResultsAnaesthesia and Intensive Care, 1987
- ISOTONIC METHOTRIMEPRAZINE BY CONTINUOUS INFUSION IN TERMINAL CANCER CAREThe Lancet, 1987
- The Use of Methotrimeprazine in Terminal CareInternational Journal Of Clinical Practice, 1985
- Midazolam A Review of its Pharmacological Properties and Therapeutic UseDrugs, 1984